



MEN

FIRST CANCER SITE  
**BONE****BONE**  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**OSSEO**  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	1567		1692		1692		1567		1212		562		248		1567	1692
Person-years ▶	7618		7890		272		1140		3220		1948		1310		7618	7890
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND BONE	65	1.06	68	1.06	3	1.19	11	1.19	21	0.83	17	1.06	16	1.48	0.46	0.51
HEAD AND NECK	4	1.41	4	1.35	0	0.00	1	2.28	2	1.66	1	1.38	0	0.00	0.15	0.13
ORAL CAVITY	2	2.94	2	2.83	0	0.00	1	9.71	1	3.51	0	0.00	0	0.00	0.17	0.16
PHARYNX	1	1.56	1	1.50	0	0.00	0	0.00	0	0.00	1	6.13	0	0.00	0.05	0.04
LARYNX	1	0.66	1	0.63	0	0.00	0	0.00	1	1.54	0	0.00	0	0.00	-0.07	-0.07
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.09	-0.09
STOMACH	4	1.09	4	1.05	0	0.00	1	1.68	1	0.65	0	0.00	2	3.39	0.05	0.02
COLON RECTUM	3	0.37	3	0.35	0	0.00	0	0.00	1	0.30	1	0.46	1	0.68	-0.68	-0.70
COLON	2	0.36	2	0.35	0	0.00	0	0.00	0	0.00	1	0.69	1	1.01	-0.46	-0.47
RECTUM	1	0.37	1	0.36	0	0.00	0	0.00	1	0.90	0	0.00	0	0.00	-0.22	-0.23
LIVER	1	0.42	1	0.41	0	0.00	0	0.00	0	0.00	0	0.00	1	2.46	-0.18	-0.19
GALLBLADDER	2	3.34	2	3.19	0	0.00	0	0.00	0	0.00	1	6.53	1	9.88	0.18	0.17
PANCREAS	1	0.63	1	0.61	0	0.00	0	0.00	0	0.00	0	0.00	1	3.62	-0.08	-0.08
LUNG	9	0.86	9	0.83	0	0.00	1	0.62	5	1.14	0	0.00	3	1.76	-0.18	-0.23
SKIN MELANOMA	2	1.78	2	1.72	0	0.00	0	0.00	0	0.00	2	6.64	0	0.00	0.11	0.11
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
KAPOSI SARCOMA	1	6.78	1	6.50	0	0.00	0	0.00	1	16.14	0	0.00	0	0.00	0.11	0.11
SOFT TISSUE	1	3.73	1	3.60	0	0.00	0	0.00	1	9.07	0	0.00	0	0.00	0.10	0.09
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
PROSTATE	11	0.99	12	1.04	1	2.33	2	1.28	0	0.00	6	2.02	3	1.41	-0.02	0.05
TESTIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.06
KIDNEY AND RENAL PELVIS	3	1.47	3	1.42	0	0.00	2	6.89	1	1.20	0	0.00	0	0.00	0.13	0.11
BLADDER AND URINARY TRACT	13	1.97	14	2.03	1	3.58	2	1.97	5	1.82	5	2.92	1	0.88	0.84	0.90
URINARY BLADDER	13	2.05	14	2.11	1	3.73	2	2.06	5	1.89	5	3.05	1	0.92	0.87	0.94
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.12	-0.12
THYROID	1	2.14	1	2.08	0	0.00	1	16.83	0	0.00	0	0.00	0	0.00	0.07	0.07
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
NON-HODGKIN LYMPHOMA	3	1.54	3	1.49	0	0.00	0	0.00	2	2.50	0	0.00	1	2.85	0.14	0.12
MYELOMA	1	1.28	1	1.23	0	0.00	0	0.00	1	3.08	0	0.00	0	0.00	0.03	0.02
LEUKAEMIAS	3	2.05	3	1.97	0	0.00	0	0.00	1	1.63	1	2.67	1	4.10	0.20	0.19
LYMPHOID LEUKAEMIAS	2	2.84	2	2.72	0	0.00	0	0.00	0	0.00	1	5.62	1	8.73	0.17	0.16
MYELOID LEUKAEMIAS	1	1.52	1	1.46	0	0.00	0	0.00	1	3.66	0	0.00	0	0.00	0.04	0.04
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	2	0.65	3	0.94	1	7.59	1	2.10	0	0.00	0	0.00	1	1.92	-0.14	-0.02

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**BONE****BONE****POOL AIRTUM 1976-2010, WOMEN:**

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

**OSSO****POOL AIRTUM 1976-2010, DONNE:**

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	1240		1327		1327		1240		969		490		241		1240	1327
Person-years ▶	6647		6861		214		917		2714		1748		1268		6647	6861
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND BONE	54	1.41	56	1.41	2	1.46	7	1.31	15	0.99	18	1.76	14	1.84	2.37	2.39
HEAD AND NECK	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.07	-0.07
ORAL CAVITY	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
PHARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
OESOPHAGUS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	-0.02
STOMACH	3	1.52	3	1.46	0	0.00	1	3.25	0	0.00	2	3.91	0	0.00	0.15	0.14
COLON RECTUM	6	1.12	6	1.08	0	0.00	0	0.00	2	0.94	3	2.13	1	0.97	0.10	0.07
COLON	6	1.58	6	1.52	0	0.00	0	0.00	2	1.33	3	2.99	1	1.35	0.33	0.30
RECTUM	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.23	-0.23
LIVER	1	1.17	2	2.24	1	28.95	0	0.00	0	0.00	1	4.50	0	0.00	0.02	0.16
GALLBLADDER	1	1.44	1	1.38	0	0.00	0	0.00	1	3.54	0	0.00	0	0.00	0.05	0.04
PANCREAS	1	0.77	1	0.74	0	0.00	0	0.00	1	1.96	0	0.00	0	0.00	-0.05	-0.05
LUNG	3	1.36	3	1.31	0	0.00	0	0.00	2	2.33	0	0.00	1	2.19	0.12	0.10
SKIN MELANOMA	3	3.23	3	3.13	0	0.00	1	8.75	0	0.00	1	3.95	1	4.64	0.31	0.30
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
KAPOSI SARCOMA	1	22.27	1	21.41	0	0.00	0	0.00	0	0.00	1	85.41	0	0.00	0.14	0.14
SOFT TISSUE	1	5.49	1	5.31	0	0.00	0	0.00	0	0.00	1	20.72	0	0.00	0.12	0.12
BONE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BREAST	10	0.93	11	0.99	1	2.83	2	1.39	3	0.72	1	0.34	4	1.81	-0.11	-0.01
CERVIX UTERI	2	3.08	2	2.98	0	0.00	0	0.00	0	0.00	1	5.90	1	8.07	0.20	0.19
CORPUS UTERI	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.27	-0.27
OVARY	2	1.58	2	1.52	0	0.00	0	0.00	1	1.97	1	2.96	0	0.00	0.11	0.10
KIDNEY AND RENAL PELVIS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.13	-0.13
BLADDER AND URINARY TRACT	4	3.11	4	3.00	0	0.00	1	5.41	2	3.93	0	0.00	1	3.98	0.41	0.39
URINARY BLADDER	4	3.34	4	3.22	0	0.00	1	5.80	2	4.22	0	0.00	1	4.26	0.42	0.40
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	2	3.39	2	3.28	0	0.00	0	0.00	0	0.00	1	6.52	1	8.69	0.21	0.20
THYROID	6	5.38	6	5.23	0	0.00	0	0.00	1	2.43	2	6.48	3	11.36	0.73	0.71
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	1	0.70	1	0.68	0	0.00	0	0.00	0	0.00	1	2.63	0	0.00	-0.06	-0.07
MYELOMA	1	1.69	1	1.63	0	0.00	1	11.69	0	0.00	0	0.00	0	0.00	0.06	0.06
LEUKAEMIAS	5	5.49	5	5.29	0	0.00	1	7.40	2	5.44	1	4.21	1	5.88	0.62	0.59
LYMPHOID LEUKAEMIAS	3	7.56	3	7.27	0	0.00	0	0.00	2	12.26	1	9.77	0	0.00	0.39	0.38
MYELOID LEUKAEMIAS	1	2.26	1	2.18	0	0.00	0	0.00	0	0.00	0	0.00	1	11.44	0.08	0.08
OTHER LEUKAEMIAS	1	14.20	1	13.62	0	0.00	1	90.66	0	0.00	0	0.00	0	0.00	0.14	0.14
OTHER AND ILL DEFINED SITES	1	0.40	1	0.38	0	0.00	0	0.00	0	0.00	1	1.51	0	0.00	-0.23	-0.23

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio